JPWO2018198842A1 - 非アルコール性脂肪性肝疾患用治療剤 - Google Patents

非アルコール性脂肪性肝疾患用治療剤 Download PDF

Info

Publication number
JPWO2018198842A1
JPWO2018198842A1 JP2019514396A JP2019514396A JPWO2018198842A1 JP WO2018198842 A1 JPWO2018198842 A1 JP WO2018198842A1 JP 2019514396 A JP2019514396 A JP 2019514396A JP 2019514396 A JP2019514396 A JP 2019514396A JP WO2018198842 A1 JPWO2018198842 A1 JP WO2018198842A1
Authority
JP
Japan
Prior art keywords
liver
fatty liver
aldehyde oxidase
mna
nicotinic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514396A
Other languages
English (en)
Japanese (ja)
Inventor
石井祐次
竹内健二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Original Assignee
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC filed Critical Kyushu University NUC
Publication of JPWO2018198842A1 publication Critical patent/JPWO2018198842A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019514396A 2017-04-23 2018-04-14 非アルコール性脂肪性肝疾患用治療剤 Pending JPWO2018198842A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017084912 2017-04-23
JP2017084912 2017-04-23
PCT/JP2018/015629 WO2018198842A1 (fr) 2017-04-23 2018-04-14 Agent thérapeutique pour la stéatose hépatique non alcoolique

Publications (1)

Publication Number Publication Date
JPWO2018198842A1 true JPWO2018198842A1 (ja) 2020-04-23

Family

ID=63920301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514396A Pending JPWO2018198842A1 (ja) 2017-04-23 2018-04-14 非アルコール性脂肪性肝疾患用治療剤

Country Status (2)

Country Link
JP (1) JPWO2018198842A1 (fr)
WO (1) WO2018198842A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500311A (ja) * 2013-12-13 2017-01-05 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500311A (ja) * 2013-12-13 2017-01-05 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DIGESTIVE DISEASES AND SCIENCES, vol. 60, no. 9, JPN6018024886, 2015, pages 2730 - 2739, ISSN: 0004742845 *
HHS PUBLIC ACCESS AUTHOR MANUSCRIPT (NAT. MED., 2015, VOL.21, NO.8, P.887-894), JPN6018024907, 1 February 2016 (2016-02-01), pages 1 - 29, ISSN: 0004742852 *
J. BIOL. CHEM., vol. 162, JPN6018024900, 1946, pages 741 - 742, ISSN: 0004742851 *
LEE E. B., ET AL.: "Metabolic Effects of ADP355, Protein-Based Adiponectin Receptor Agonist, on Mice with High-Fat Diet", HORM. RES. PAEDIATR., vol. vol.84, suppl.1, JPN6018024890, 2015, pages 48 - 8, ISSN: 0004742847 *
MOLECULAR MEDICINE REPORTS, vol. 14, JPN6018024892, 2016, pages 5385 - 5394, ISSN: 0004742848 *
NUTRITION RESEARCH, vol. 40, JPN6018024908, 14 March 2017 (2017-03-14), pages 40 - 47, ISSN: 0004742853 *
THE JOURNAL OF TOXICOLOGICAL SCIENCES, vol. 37, no. 5, JPN6018024884, 2012, pages 931 - 942, ISSN: 0004742844 *
THE JOURNAL OF TOXICOLOGICAL SCIENCES, vol. 40, no. 2, JPN6018024882, 2015, pages 181 - 191, ISSN: 0004742843 *
ZHANG LIANG, ET AL.: "Investigation on the influence of adiponectin on aldehyde oxidase-1 expression of hepatic cell lines", LABORATORY MEDICINE, vol. 27, no. 4, JPN6018024888, 2012, pages 275 - 279, ISSN: 0004742846 *
原 眞純，他: "ニコチン酸はMonosodium glutamate投与マウスの脂肪肝を著明に改善させるが食後高血糖をきたす", 肥満研究, vol. 19, JPN6018024897, 2013, pages 165 - 136, ISSN: 0004742850 *
広瀬 亨，他: "非アルコール性脂肪肝炎（ＮＡＳＨ）治療におけるＡＴ１レセプターブロッカーによる高血圧改善の意義", 日本内科学会雑誌, vol. 96, JPN6018024894, 2007, pages 175 - 285, ISSN: 0004742849 *
竹内 健二 他: "コリン欠乏食誘発脂肪肝モデルラットを用いたDehydroepiandrosterone sulfateおよびPhenobarbital投与によ", 第３３回 日本薬学会九州支部大会講演要旨集, vol. 33, JPN6018024880, 2016, pages 112, ISSN: 0004742842 *

Also Published As

Publication number Publication date
WO2018198842A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
Fucho et al. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis
Chenxu et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress
JP2019511478A (ja) Ｆｘｒアゴニストを使用するための方法
KR102537043B1 (ko) 조합 치료요법용 약학 조성물
US9616033B2 (en) Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities
CN111182904A (zh) 包含acc抑制剂的组合治疗
CN110430876A (zh) 用于组合疗法的药物组合物
KR20110107287A (ko) 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
EP1622605B1 (fr) Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
Li et al. Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice
AU2021273154A1 (en) Combination treatment of liver disorders
Diaz et al. Differential effects of resveratrol on the dilator responses of femoral arteries, ex vivo
WO2018198842A1 (fr) Agent thérapeutique pour la stéatose hépatique non alcoolique
US11458155B1 (en) Active ingredient complexes, compositions and methods for hangover relief and to ameliorate alcohol-induced liver damage
KR20200094175A (ko) 간 질병의 치료를 위한 fxr 작용제
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
CN114667142A (zh) 治疗肝脏病症
CN114502198A (zh) 包括使用fxr激动剂的治疗
JP2008508312A (ja) 筋肉エネルギー産生増強目的のためのメチルピルベートの用途
WO2019099509A1 (fr) Utilisation d'un antagoniste du récepteur p2x7 pour traiter une maladie ou un trouble inflammatoire
EP4331587A1 (fr) Composition pour la prévention ou le traitement de maladies métaboliques, contenant un composé de dérivé tricyclique
KR101572311B1 (ko) 2-아미노-2-노보네인카르복실산을 함유하는 비만 예방 또는 치료용 조성물
US20240051922A1 (en) Xanthohumol derivatives and methods for making and using
KR20220002047A (ko) 지페노사이드 화합물을 포함하는 간 질환 예방 또는 치료용 조성물
Kim et al. Quercetin inhibits body weight gain and adipogenesis via matrix metalloproteinases in mice fed a high-fat diet.

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20200121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004